Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients-Reference-Cited by-同舟云学术

Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients

Published:2014-10-30 Issue:1 Volume:5 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Kim Tae Jin,Jin Hyun-Tak,Hur Soo-Young,Yang Hyun Gul,Seo Yong Bok,Hong Sung Ran,Lee Chang-Woo,Kim Suhyeon,Woo Jung-Won,Park Ki Seok,Hwang Youn-Young,Park Jaehan,Lee In-Ho,Lim Kyung-Taek,Lee Ki-Heon,Jeong Mi Seon,Surh Charles D.,Suh You Suk,Park Jong Sup,Sung Young Chul

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms6317.pdf

Reference60 articles.

1. Einstein, M. H. et al. Clinician’s guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect. Dis. 9, 347–356 (2009).

2. Parkin, D. M. & Bray, F. Chapter 2: The burden of HPV-related cancers. Vaccine 24, (Suppl 3): S3/11–25 (2006).

3. Schiffman, M., Castle, P. E., Jeronimo, J., Rodriguez, A. C. & Wacholder, S. Human papillomavirus and cervical cancer. Lancet 370, 890–907 (2007).

4. Forman, D. et al. Global burden of human papillomavirus and related diseases. Vaccine 30, (Suppl 5): F12–F23 (2012).

5. de Vos van Steenwijk, P. J. et al. Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response. Clin. Cancer Res. 14, 7188–7195 (2008).

Cited by 200 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the Efficacy of Active Hexose Correlated Compound as an Adjuvant in Reducing Recurrence After Condyloma Cauterization;2024-09-12

2. Recent Advancements in mRNA Vaccines: From Target Selection to Delivery Systems;Vaccines;2024-08-01

3. Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies;Molecular Therapy;2024-07

4. Enhanced the immunity activity of HPV16 DNA vaccine by the combination CpG oligonucleotides adjuvant cloned into plasmid backbone and IL-28B gene adjuvant;2024-05-13

5. Immunogenicity and effectiveness of an mRNA therapeutic vaccine for HPV-related malignancies;Life Science Alliance;2024-03-21